Treatment of Pain in Cancer: Towards Personalised Medicine.

Abstract

Despite increased attention to cancer pain, pain prevalence in patients with cancer has not improved over the last decade and one third of cancer patients on anticancer therapy and half of patients with advanced disease still suffer from moderate to severe pain. In this review, we explore the possible reasons for the ongoing high prevalence of cancer pain and discuss possible future directions for improvement in personalised pain management. Among possible reasons for the lack of improvement are: Barriers for patients to discuss pain with clinicians spontaneously; pain measurement instruments are not routinely used in daily practice; limited knowledge concerning the assessment of undertreatment; changes in patients' characteristics, including the ageing of the population; lack of significant improvement in the treatment of neuropathic pain; limitations of pharmacological treatment and lack of evidence-based nonpharmacological treatment strategies. In order to improve cancer pain treatment, we recommend: (1) Physicians proactively ask about pain and measure pain using assessment instruments; (2) the development of an optimal tool measuring undertreatment; (3) educational interventions to improve health care workers' skills in pain management; (4) the development of more effective and personalised pharmacological and nonpharmacological pain treatment.

• Authors: Marieke H J van den Beuken-van Everdingen, Sander M J van Kuijk, Daisy J A Janssen, Elbert A J Joosten
• Journal: Cancers (Cancers (Basel)) Vol. 10 Issue 12 (Dec 10 2018) ISSN: 2072-6694 [Print] Switzerland
• PMID: 30544683 (Publication Type: Journal Article, Review)